When did Atrium Therapeutics report Q1 2026 earnings?

Atrium Therapeutics (RNA) reported Q1 2026 earnings on May 14, 2026 before market open.

What were Atrium Therapeutics 's Q1 2026 revenue and EPS?

Atrium Therapeutics reported revenue of $19.6M and eps of $-0.97 for Q1 2026.

Revenue beat the consensus estimate of $2.0M by $17.6M. EPS beat the consensus estimate of $-1.05 by $0.08.

Reported May 14, 2026 · Before market open

Revenue$19.6MBeat by $17.6M

EPS-$0.97Beat by $0.08

Revenue estimate$2.0M

EPS estimate-$1.05

Aug 13, 2026 (In 2 weeks)

Revenue estimate$666.7K

EPS estimate-$1.18

Q1 2026$19.6MBeat by $17.6M

Q1 2026-$0.97Beat by $0.08

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Atrium Therapeutics report Q1 2026 earnings?: Atrium Therapeutics (RNA) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Atrium Therapeutics 's Q1 2026 revenue and EPS?: Atrium Therapeutics reported revenue of $19.6M and eps of $-0.97 for Q1 2026.
Did Atrium Therapeutics beat estimates in Q1 2026?: Revenue beat the consensus estimate of $2.0M by $17.6M. EPS beat the consensus estimate of $-1.05 by $0.08.